Belatacept and Long-Term Outcomes in Kidney Transplantation

2016743 citationsJournal Articlebronze Open Access

Authors

Flavio Vincenti · University of California, San Francisco

Lionel Rostaing · Inserm

J.M. Boria Grinyo · Bellvitge University Hospital

Kim Rice · Baylor University Medical Center

Steven Steinberg · Sharp Memorial Hospital

Luis Gaite · Centro Científico Tecnológico - Santa Fe

Marie‐Christine Moal

Abstract

Seven years after transplantation, patient and graft survival and the mean eGFR were significantly higher with belatacept (both the more-intensive regimen and the less-intensive regimen) than with cyclosporine. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00256750.).

Topics & Keywords

Renal Transplantation Outcomes and Treatments Organ Transplantation Techniques and Outcomes Complement system in diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 374, Issue 4, pp. 333-343

DOI: 10.1056/nejmoa1506027

Field-Weighted Citation Impact: 69.96